drug

JNJ-39393406

MeSH C000630150
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Janssen, L.P. - Investigator Initiated Studies Program
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
NCT01137799Phase 1Terminated

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Janssen, L.P. - Investigator Initiated Studies Program
company
trial
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
PHASE1
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Cognition Disorders
indication
Alzheimer Disease
indication